Početna stranicaNOVN • SWX
add
Novartis
VrijednosnicaPredvodnik u zaštiti okolišaZemlja u kojoj se trguje vrijednosnicom: CHZemlja u kojoj se nalazi sjedište: CH
Preth. zaklj. cijena
91,56 CHF
Dnevni raspon
92,04 CHF - 93,99 CHF
Godišnji raspon
83,63 CHF - 102,72 CHF
Tržišna kapitalizacija
205,76 mlr. CHF
Prosječna količina
2,97 mil.
P/E omjer
12,39
Prinos dividende
3,52 %
Glavno tržište vrijednosnica
SWX
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 13,17 mlr. | 8,93 % |
Operativni troškovi | 5,52 mlr. | −24,45 % |
Neto dohodak | 3,19 mlr. | 81,09 % |
Neto profitabilnost | 24,21 | 66,28 % |
Zarada po dionici | 2,06 | 18,39 % |
EBITDA | 5,50 mlr. | 88,62 % |
Efektivna porezna stopa | 5,91 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 13,85 mlr. | 8,08 % |
Ukupna imovina | 103,52 mlr. | −8,14 % |
Ukupne obveze | 60,08 mlr. | −19,30 % |
Ukupni kapital | 43,44 mlr. | — |
Dionice u optjecaju | 2,00 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 4,23 | — |
Povrat imovine | 10,97 % | — |
Povrat kapitala | 15,05 % | — |
Tok novca
Neto promjena novca
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | 3,19 mlr. | 81,09 % |
Gotovina od poslovanja | 6,29 mlr. | 16,88 % |
Gotovina iz ulaganja | −374,00 mil. | 83,09 % |
Gotovina iz financiranja | −382,00 mil. | 54,09 % |
Neto promjena novca | 5,71 mlr. | 275,39 % |
Slobodan tok novca | 4,55 mlr. | −63,57 % |
Više
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes”.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Glavni izvršni direktor
Osnovano
29. velj 1996.
Sjedište
Web-lokacija
Zaposlenici
76.057